Cargando…

Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab

BACKGROUND: The immunosuppressive tumor microenvironment (TME) contributes to the tumor progression and treatment failure. Our previous study demonstrated alterations in the TME during bevacizumab (Bev) therapy in human glioblastoma (GB) specimens obtained from patients who underwent surgical resect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Ryota, Tanaka, Toshihide, Morimoto, Yukina, Kuranari, Yuki, Yamamoto, Yohei, Takei, Jun, Murayama, Yuichi, Yoshida, Kazunari, Sasaki, Hikaru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186631/ https://www.ncbi.nlm.nih.gov/pubmed/32355741 http://dx.doi.org/10.21037/atm.2020.03.11

Ejemplares similares

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2018)

“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
por: Yamamoto, Yohei, et al.
Publicado: (2017)

ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA
por: Tanaka, Toshihide, et al.
Publicado: (2019)

Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas
por: Takei, Jun, et al.
Publicado: (2022)

ANGI-1 Impact of neoadjuvant bevacizumab on transcriptional factor for stemness, macrophage polarization, and oxygenation of tumor microenvironment in glioblastoma
por: Tanaka, Toshihide, et al.
Publicado: (2021)

Histopathological investigation of glioblastomas resected under bevacizumab treatment
por: Tamura, Ryota, et al.
Publicado: (2016)

Long-Term Clinical Outcome of First Recurrence Skull Base Meningiomas
por: Kuranari, Yuki, et al.
Publicado: (2019)

Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients With Meningiomas
por: Kuranari, Yuki, et al.
Publicado: (2020)

A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
por: Tamura, Ryota, et al.
Publicado: (2020)

Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors
por: Sato, Mizuto, et al.
Publicado: (2019)

Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series
por: Tamura, Ryota, et al.
Publicado: (2020)

Correction to: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series
por: Tamura, Ryota, et al.
Publicado: (2020)

Severe headache in a patient with meningioma showing extensive dural tail correlates with IgG4-positive plasma cells and eosinophils: A case report and review of literature
por: Kuranari, Yuki, et al.
Publicado: (2018)

GCT-51. IMMUNE CHECKPOINT MOLECULES AND TUMOR INFILTRATING LEUKOCYTES IN THE TUMOR MICROENVIRONMENT ARE ASSOCIATED WITH THE GROWTH OF INTRACRANIAL GERMINOMAS
por: Nishimoto, Masaaki, et al.
Publicado: (2020)

ANGI-1 ASSESSING THE THERAPEUTIC EFFECT OF BEVACIZUMAB USING FMISO-PET IN GBM THERAPY
por: Suzuki, Tomoya, et al.
Publicado: (2022)

IMT-02 VEGF RECEPTORS EXPRESSION AND REPORT OF CLINICAL TRIAL OF PEPTIDE VACCINE IN SKULL BASE CHORDOMA
por: Morimoto, Yukina, et al.
Publicado: (2019)

COT-08 Analysis of prognosis of biopsy/partial resection cases of malignant glioma
por: Yamamoto, Yohei, et al.
Publicado: (2020)

A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma
por: Kikuchi, Ryogo, et al.
Publicado: (2019)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

A Three-Surgeon–Six-Hand Operation Using a 4K-3D Exoscope for Neurological Surgery: A Case Report
por: Tamura, Ryota, et al.
Publicado: (2022)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
por: Chen, Zhaoyan, et al.
Publicado: (2020)

Chronic Encapsulated Expanding Thalamic Hematoma Associated with Obstructive Hydrocephalus following Radiosurgery for a Cerebral Arteriovenous Malformation: A Case Report and Literature Review
por: Takei, Jun, et al.
Publicado: (2016)

IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
por: Akasaki, Yasuharu, et al.
Publicado: (2021)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma
por: Jang, Yena, et al.
Publicado: (2023)

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report
por: OKITA, YOSHIKO, et al.
Publicado: (2015)

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
por: Carter, Tonia C., et al.
Publicado: (2018)

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment
por: Darmon, Ilan, et al.
Publicado: (2017)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

Meningioma Cell Invasion into DuraGen-Derived Dura Mater: A Case Report
por: Tamura, Ryota, et al.
Publicado: (2022)

Suboccipital trans-horizontal fissure approach for cerebellar hemorrhage with rupture into the upper fourth and third ventricles: the first clinical experience. Illustrative cases
por: Tamura, Ryota, et al.
Publicado: (2022)

IMT-01 THERAPEUTIC EFFECT AGAINST LOWER GRADE GLIOMA INDUCED BY DENDRITIC CELL BASED IMMUNOTHERAPY
por: Akasaki, Yasuharu, et al.
Publicado: (2019)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma
por: Takei, Jun, et al.
Publicado: (2023)

A case of acute subdural hematoma due to bleeding from metastatic chondrosarcoma of the skull
por: Kosugi, Kenzo, et al.
Publicado: (2017)

GCT-55. INTRACRANIAL GERMINOMA ORIGINATING FROM ATYPICAL LOCATION WITH SUBCLINICAL ADH INSUFFICIENCY
por: Kuranari, Yuki, et al.
Publicado: (2020)

Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment
por: Xue, Wei, et al.
Publicado: (2017)

Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death
por: YAMAMOTO, Yutaro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_68egjc4csegb0cg1mupvg4tb1n